Pharmaceuticals Announces Fiscal Year 2019

Pharmaceuticals Announces Fiscal Year 2019

Financial Results and Recent Corporate Updates

Company Estimates Cash Runway Sufficient to Report Top-Line

Results from Two of Three Patient Groups in Phase 2 Trials By 4th Quarter of Calendar Year 2020

SAN DIEGO, California, September 10, 2019 /PRNewswire/ -- DelMar

Pharmaceuticals, Inc. (Nasdaq: DMPI) ("DelMar" or the "Company"), a biopharmaceutical company focused on

the development of new cancer therapies, announced its financial results for the year ended June 30, 2019.

"This has been a productive quarter and year for DelMar

as we have achieved multiple data milestones for both of our Phase 2 GBM trials for VAL-083," commented Saiid Zarrabian,

DelMar's President and Chief Executive Officer. "Most importantly, based on recent budget refinements, we now believe

we have sufficient capital to achieve release of topline data for two of our three currently enrolling MGMT-unmethylated GBM patient

groups. These topline results include the recurrent setting GBM trial being conducted at the MD Anderson Cancer Center and the

first line GBM trial being conducted at Sun Yat-sen University Cancer Center in China. We anticipate results from both of these

trials to be announced during the fourth quarter of calendar year 2020 and will be supported by the Company's recent financings

completed in June and August 2019. Additionally, we have also relocated our headquarters to San Diego to position ourselves for

better access to required expertise as we advance our trials."

RECENT CORPORATE UPDATES

SUMMARY OF FINANCIAL RESULTS FOR FISCAL YEAR ENDED JUNE 30,

At June 30, 2019, the Company had cash and cash equivalents

on hand of approximately $3.7 million. In August 2019, the Company completed an underwritten public offering for net proceeds of

approximately $6.7 million. The proceeds from the August 2019 financing combined with cash and cash equivalents on hand at June

30, 2019 are expected to be sufficient to fund the Company's planned operations into the fourth quarter of calendar year

For the year ended June 30, 2019, the Company reported a net

loss of approximately $8.0 million, or $3.16 per share, compared to a net loss of approximately $11.1 million, or $5.42 per share,

for the year ended June 30, 2018.

Selected Balance Sheet data

Selected Statement of operations data

DelMar's financial statements as filed with the U.S. Securities

Exchange Commission can be viewed on the Company's website at: http://ir.delmarpharma.com/all-sec-filings.

ABOUT DELMAR PHARMACEUTICALS, INC.

Located in San Diego, California, DelMar is focused on the development

and commercialization of new therapies for cancer patients who have limited or no treatment options. By focusing on understanding

tumor biology and mechanisms of treatment resistance, the Company identifies biomarkers to personalize new therapies in indications

where patients are failing, or are unable to tolerate, standard-of-care treatments.

The Company's current pipeline is based around VAL-083,

a "first-in-class", small-molecule chemotherapeutic with a novel mechanism of action that has demonstrated clinical

activity against a range of cancers, including central nervous system, ovarian and other solid tumors (e.g. NSCLC, bladder cancer,

head & neck) in U.S. clinical trials sponsored by the National Cancer Institute (NCI). Based on DelMar's internal research

programs and these prior NCI-sponsored clinical studies, the Company is conducting clinical trials to support the development and

commercialization of VAL-083 to solve significant unmet medical needs.

VAL-083 is being studied in two collaborator-supported, biomarker-driven

Phase 2 clinical trials for MGMT-unmethylated GBM. Overcoming MGMT-mediated resistance represents a significant unmet medical need

in the treatment of GBM. In addition, DelMar has announced the allowance of a separate IND for VAL-083 as a potential treatment

for platinum-resistant ovarian cancer.

Further information on DelMar's clinical trials can be

found on clinicaltrials.gov: https://www.clinicaltrials.gov/ct2/results?cond=&term=val-083&cntry1=&state1=&recrs

For additional information, please visit http://delmarpharma.com/;

or contact DelMar Pharmaceuticals Investor Relations: ir@delmarpharma.com / (604) 629-5989.

SAFE HARBOR STATEMENT

Any statements contained in this press

release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private

Securities Litigation Reform Act of 1995, including statements regarding the status of the Company's clinical trials and

the reporting of the results. Any forward-looking statements contained herein are based on current expectations but are subject

to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations

include, but are not limited to, risks and uncertainties relating to the Company's ability to develop, market and sell products

based on its technology; the expected benefits and efficacy of the Company's products and technology; the availability of substantial

additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future

product commercialization; and, the Company's business, research, product development, regulatory approval, marketing and distribution

plans and strategies. These and other factors are identified and described in more detail in the Company's filings with the

SEC, including the Company's Annual Report on Form 10-K for the year ended June 30, 2019, the Company's Quarterly Reports

on Form 10-Q, and the Company's Current Reports on Form 8-K.

Director of Public Relations